On October 1, 2025 Neogap Therapeutics AB, a Swedish biotechnology company developing personalised cancer immunotherapy, reported it has been granted a Chinese patent for its method of expanding tumour-specific T cells – a key component of the company’s therapeutic approach (Press release, Neogap Therapeutics, OCT 1, 2025, View Source,c4243370 [SID1234656382]). The grant strengthens Neogap’s international IP position and supports its long-term strategy to protect and advance its proprietary technologies globally.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Chinese patent covers a process used to produce Neogap’s personalised cell-based immunotherapy, pTTL, which is currently under evaluation in a Phase I/II clinical trial for advanced colorectal cancer.
This patent provides legal protection in China until 2038 and further strengthens Neogap’s international intellectual property portfolio in a strategically important market for advanced therapies. China is one of the world’s largest and fastest-growing life science markets, making this grant an important step in the company’s global IP strategy.
It follows the grant of an equivalent patent in Europe in 2023, along with other IP approvals in Europe and other key markets, and the classification of pTTL as an Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency. These developments reflect Neogap’s coordinated strategy to protect its key technologies and strengthen the company’s position as clinical work progresses.
"This patent protects our core method for producing tumour-specific T cells, which underpins Neogap’s immunotherapy," says Samuel Svensson, CEO of Neogap Therapeutics.
"Strong international IP protection is critical as we advance in clinical development – not only to enable future partnerships, but to reinforce the global credibility of our technology. Patent protection in China, one of the world’s largest and fastest-growing life science markets, also supports our long-term ambition to deliver innovative therapies for patients with hard-to-treat cancer."
The patented method enables the ex vivo expansion of tumour-specific T cells by exposing them to selected antigens, facilitating the production of therapeutic cell populations with improved tumour reactivity. The method forms part of Neogap’s proprietary EpiTCer technology, and has previously been granted patent protection in Europe.